Tadaaki Taniguchi
Chief R&D Officer
Bio:
Dr. Tadaaki Taniguchi serves as Chief Research & Development Officer at Astellas where he oversees a global team responsible for identifying, discovering and developing treatments with
the potential to reshape expectations of medical care. His responsibility covers multiple functions focused on developing innovative and patient-centric treatments and ensuring their
appropriate and safe use throughout a product’s lifecycle. These functions include Research and Development (in areas like Cell & Gene Therapy, Oncology), Primary Focus Leads
(Blindness & Regeneration, Genetic Regulation, Immuno-Oncology, Targeted Protein Degradation), Regulatory Affairs, Pharmacovigilance, Quantitative Science & Clinical
Operations as well as Strategy and Operations.
Tadaaki joined Astellas as Chief Medical and Development Officer in July 2022 with more than 20 years of industry experience spanning research, development, and medical affairs. He has worked across a range of therapeutic areas, including diabetes and oncology, to deliver transformational medicines to patients. Prior to joining Astellas, Tadaaki held senior roles in major multinational pharmaceutical companies in the U.S., Japan and China operating at global and regional levels.
Tadaaki completed a Ph.D. in Medicine at Imperial College London, and earned his Doctor of Medicine degree from Tottori University in Japan. As a surgical oncologist, he spent 10 years working in clinics and research laboratories. The knowledge and experience he gained contributed to his unique perspective on how global pharmaceutical companies can innovate to deliver breakthrough science by rethinking approaches to medicine that change the way
diseases are treated.